« BACK

Thursday, March 11, 2010 :: IMAGING DIAGNOSTIC SYSTEMS EXHIBITS AT THE 2010 EUROPEAN COLLEGE OF RADIOLOGY CONFERENCE
IMAGING DIAGNOSTIC SYSTEMS EXHIBITS AT THE 2010 EUROPEAN COLLEGE OF RADIOLOGY CONFERENCE


Fort Lauderdale, Florida, March 11, 2010—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging; exhibited its CT Laser Mammography (CTLM®) system at the European College of Radiology, March 4-8, 2010, in Vienna, Austria. ECR 2010 had over 19,000 international delegates, an increase of attendance over the previous years.

The European College of Radiology (ECR) is the annual meeting for the European Society of Radiology. It is a trend-setting, dynamic and service-oriented congress, well-known as one of the most innovative meetings within the scientific community. It's the fastest growing medical society in the world, currently with over 45,000 members. ECR attracts over 18,000 delegates and is the second largest radiological congress worldwide. The European Congress of Radiology represents the medical specialty of radiology throughout Europe and the Mediterranean. The ECR comprises a Congress Committee, a Program Planning Committee, a Technical Exhibition Committee, and 15 Scientific Subcommittees.

"Attending the ECR is essential, as it provides an opportunity to showcase our CTLM system and personally meet with our clinical partners and established customers. In addition, it offers us the opportunity to introduce our technology to new customers and meet prospective distributors," commented Deborah O'Brien/Imaging Diagnostic Systems, Inc.
About Imaging Diagnostic Systems, Inc
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

The Company is currently undergoing the clinical studies required for the Premarket approval application. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.